FDA officials asked to step down after contentious Alzheimer’s drug approval
arstechnica.com
arstechnica.com
I expect it will actually be overturned, given what happened with Vioxx.
I'm going with the grey option and say that FDA should approve drugs primarily based on harm, with a note on usefulness. It then should be the decision of other regulatory bodies, or even better doctors whether the harm is worth the benefit for each individual case. And definitely there should be a separate decision on whether it's covered by Medicare - makes absolutely no sense to spend good money on a shady drug just because it got FDA stamp.